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Introduction {#sec1}
============

Dravet syndrome (DS) is a severe and intractable developmental and epileptic encephalopathy characterized by pharmacoresistant seizures, cognitive impairment, and increased mortality. The majority of DS patients carry *de novo* variants in *SCN1A* that result in haploinsufficiency for the voltage-gated sodium channel (VGSC) Na~v~1.1 ([@bib5], [@bib23]). Up to 20% of DS patients die from sudden unexpected death in epilepsy (SUDEP) ([@bib6]). Indirect evidence has linked SUDEP to central or obstructive apnea, pulmonary edema, dysregulation of cerebral circulation, autonomic dysfunction, or cardiac arrhythmias ([@bib29]). While SUDEP is the most devastating consequence of epilepsy, very little is understood about its causes and there are no biomarkers to predict which patients are at increased risk for SUDEP. Because *SCN1A* is expressed in heart as well as in brain ([@bib22], [@bib24]), we proposed that alterations in cardiac excitability may contribute to the mechanism of SUDEP in *SCN1A*-linked DS. Here, we used DS patient induced pluripotent stem cell-derived cardiac myocytes (iPSC-CMs) to test this hypothesis.

The cardiac action potential (AP) is a tightly regulated process that relies on the ability of ion channels to depolarize and repolarize in synchrony to maintain proper heart rhythm ([@bib27]). Mutations in cardiac VGSC genes result in arrhythmias ([@bib33]). Tetrodotoxin (TTX)-resistant Na~v~1.5 channels, encoded by *SCN5A*, are the major cardiac VGSCs in mammals ([@bib3]). Na~v~1.1, a TTX-sensitive VGSC that is highly expressed in brain ([@bib35]), is also expressed in human and mouse heart, although at lower levels than Na~v~1.5 ([@bib22], [@bib24]). Work in rodents indicates that TTX-sensitive VGSCs, including Na~v~1.1, are expressed in specific cardiac subcellular domains where they play important roles in shaping the cardiac AP and modulating excitation-contraction coupling ([@bib9], [@bib16], [@bib19], [@bib20], [@bib25], [@bib34]). We showed previously that *Scn1a*^*R1407X*^ and *Scn1b* null DS mouse CMs have compensatory increases in transient and persistent sodium current (I~Na~) and increased incidence of early afterdepolarizations in the AP waveform ([@bib2], [@bib16], [@bib18]). This work demonstrated that, in addition to aberrant central and peripheral neuronal excitability ([@bib13], [@bib37]), DS mice have differences in CM ionic currents that serve as substrates for arrhythmias. Importantly, our work suggested that cardiac arrhythmias contribute to the mechanism of SUDEP in DS patients.

While transgenic mouse models have provided valuable insights into potential SUDEP mechanisms, mice are not small humans. As a result, no biomarkers exist to assess SUDEP risk in patients. To address this problem, we have generated CMs from *SCN1A*-DS patient-derived iPSCs. Importantly, iPSC-CMs retain the patient\'s unique genetic background. In addition, cellular phenotypes are autonomous; changes in ionic currents are intrinsic to the cell rather than the result of remodeling in response to altered autonomic innervation or seizures, as might occur in the whole animal. Here, we generated iPSC-CMs from 4 *SCN1A*-linked DS subjects and two controls without epilepsy and measured contraction rates and VGSC function. Our results were predictive of altered cardiac electrophysiology in one subject before cardiac symptoms were diagnosed.

Results {#sec2}
=======

Skin biopsies were collected from four *SCN1A-*linked DS patients and two controls without epilepsy under Institutional Review Board approval. [Table 1](#tbl1){ref-type="table"} characterizes the patient *SCN1A* mutations as well as their clinical parameters. Reprogramming and pluripotency analyses were described previously ([@bib17]). To generate iPSC-CMs we used chemically defined, growth factor-free media containing small-molecule Wnt inhibitors ([@bib15]). Following at least 60 days of maturation, iPSC-CMs had an elongated morphology ([Figures 1](#fig1){ref-type="fig"}A--1C and [2](#fig2){ref-type="fig"}B). Immunofluorescence staining ([Figures 1](#fig1){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}) showed that both patient and control iPSC-CMs expressed α-actinin ([Figures 1](#fig1){ref-type="fig"}A--1C and [S1](#mmc1){ref-type="supplementary-material"}A--S1E), connexin 43 ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A--S1E), Nav1.5 ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}A--S1E), and the homeobox transcription factor NKX2.5 ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}A--S1E).Table 1Clinical Characterization of DS PatientsDS2DS4DS5DS10SexMMFF*SCN1A* mutationc.975T\>A (p.Y325X)c.3982T\>C (p.S1328P)c.664C\>T (p.R222X)c.G965\>T (p.R322I)Sample typefibroblastsfibroblastsfibroblastsfibroblastsAge at skin biopsy (years)77210Notescardiac evaluation at age 4 years showed abnormal T-wave inversions and lateral T-wave flatteningafter this study, was diagnosed with Wolff-Parkinson-White syndrome and underwent successful ablationFigure 1Immunofluorescence Staining and Spontaneous Contraction Rates of iPSC-CMs(A) Anti-α-actinin (red) and anti-connexin 43 (green) staining for DS5.(B) Anti-α-actinin (red) and anti-Nav1.5 (green) staining for DS5.(C) Anti-α-actinin (red) and anti-NKX 2.5 (green) staining for DS5.(D) Increased contraction rates in DS iPSC-CM lines compared with control. Data from two independent control lines were pooled. For DS4, DS10, and DS5, data from two independent clones were pooled. For all lines, data were collected from 4--6 wells of one differentiation. ^∗^p \< 0.05.(E) Representative MEA traces from control (left) and DS (right) iPSC-CM lines.(F) Quantification of contraction rates in MEA recordings. For control 3 (Con 3) and DS4, data were pooled from two different clones, with two independent differentiations per clone. ^∗^p \< 0.05. Immunofluorescence staining of DS2, DS4, and DS10 is shown in [Figure S1](#mmc1){ref-type="supplementary-material"}.Data in (E) and (F) are presented as means ± SEM. Scale bar, 20 μm (A--C). See also [Figure S2](#mmc1){ref-type="supplementary-material"}.Figure 2iPSC-CMs from DS Patients Have Increased Whole-Cell I~Na~ and Altered *SCN5A* Expression(A) Representative whole-cell I~Na~ traces from a control and three DS subjects.(B) Representative images of control 2 (Con 2) and DS5 iPSC-CMs used in electrophysiological recordings.(C) I~Na~ current-voltage relationships for control and three DS iPSC-CM lines.(D) Peak I~Na~ is increased in all four DS iPSC-CM lines compared with controls. ^∗^p \< 0.05 versus control; ^\#^p \< 0.05 versus average of DS2, DS4, and DS10.(E) Current-voltage relationship comparing DS5 to control. Inset: representative I~Na~ trace from DS5. Peak I~Na~ data were pooled from two clones each for DS4, DS10, and DS5, respectively. Peak I~Na~ data for the control group were pooled from two independent control iPSC-CM lines (Con 2, 1 clone; Con 3, two clones). Data comparing the two control lines are shown in [Figure S3](#mmc1){ref-type="supplementary-material"}. At least two independent differentiations were analyzed per line (Con 2, 3; Con 3-1, 2; Con 3-3, 2; DS2-3, 3; DS4-3, 3; DS4-4, 2; DS10-2, 4; DS10-7, 2; DS5-1, 2; DS5-2, 2).(F) qRT-PCR data from male and female control iPSC-CM lines, pooled DS patient iPSC-CMs, and adult human heart control tissue.Data in (C), (D), and (E) are presented as means ± SEM for all groups. For (F), data for DS samples are presented as means ± SEM (n = 4). See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}; [Table S1](#mmc1){ref-type="supplementary-material"}.

iPSC-CMs spontaneously contract in monolayer culture ([@bib38]). Video recordings of the contracting monolayers showed a higher rate of contraction for DS patient iPSC-CMs compared with controls, with no differences between DS patient lines ([Figures 1](#fig1){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}; [Video S1](#mmc2){ref-type="supplementary-material"}). We used multi-electrode array (MEA) recordings as an independent approach to assess contraction rates. Two lines, control 3 and DS4, were tested using this method. In agreement with visually quantified rate differences, the firing rate in the MEA recordings was increased in DS4 compared with control ([Figures 1](#fig1){ref-type="fig"}E, 1F, and [S2](#mmc1){ref-type="supplementary-material"}C).

Video S1. Beating Patterns in Cultures of Dravet Syndrome and Control iPSC-CMs

We performed whole-cell voltage-clamp recordings to investigate whether iPSC-CMs from DS patients had altered I~Na~ density due to compensatory expression of other VGSC genes, as observed in DS mouse models ([@bib2], [@bib18]). Transient I~Na~ density was increased at least 1.5-fold in all four DS iPSC-CM lines (1.57-fold for DS2, 1.80-fold for DS4, 1.74-fold for DS10, and 2.37-fold for DS5) over control lines ([Figures 2](#fig2){ref-type="fig"}A and 2C--2E; [Table S1](#mmc1){ref-type="supplementary-material"}). Current density in the DS5 CMs was so large that proper voltage control could not be consistently maintained and voltage-dependent properties could not be accurately measured ([Figure 2](#fig2){ref-type="fig"}E, inset; [Table S1](#mmc1){ref-type="supplementary-material"}), thus the value reported for I~Na~ density is likely an underestimate of the true increase. The increase in DS5 I~Na~ density was significantly greater than the average increase observed in the other three DS patient lines (p = 0.03; [Figure 2](#fig2){ref-type="fig"}D and [Table S1](#mmc1){ref-type="supplementary-material"}). We found no changes in persistent I~Na~ density between control and DS lines. DS10 showed a small but significant decrease in τ for the fast component of inactivation at −30 mV, with no changes in τ for the slow phase of inactivation between control and DS lines. DS4 and DS10 showed small but significant positive shifts in the voltage dependence of inactivation, with DS4 also showing a reduced slope of the inactivation curve compared with control. DS2 and DS10 showed negative shifts in the voltage dependence of activation as well as decreases in activation slope compared with control ([Table S1](#mmc1){ref-type="supplementary-material"}).

We performed qRT-PCR ([Figure 2](#fig2){ref-type="fig"}F) to assess changes in the level of VGSC mRNA expression in DS patient iPSC-CMs compared with control iPSC-CMs and non-failing adult human heart. While there were measurable differences in *SCN5A* mRNA expression between the male and female control lines (1.9-fold increase in total *SCN5A* in female over male, 4.5-fold increase in *SCN5A-6* in female over male, and 3.7-fold increase in *SCN5A-6A* in female over male), there were no consistent differences in expression between the male and female DS lines, so the data for these lines were pooled. We observed increased total *SCN5A* expression in DS iPSC-CMs over the male control iPSC-CM line (3.2-fold) and over the female control line (1.7-fold), with adult human heart showing a 9.9-fold increase compared with the male control and a 5.2-fold increase compared with the female control. We also used specific primers to differentiate between adult (*SCN5A-6*) and embryonic (*SCN5A-6A*) splice variants of *SCN5A*. We observed a 4.6-fold increase in the combined DS iPSC-CM data over the male control but no difference compared with the female control. The DS iPSC-CM data also showed a 5.2-fold increase in the embryonic (*SCN5A-6A*) splice variant over the male control and a 1.5-fold increase over the female control. As expected, non-failing adult human heart had high levels of *SCN5A-6* with almost undetectable levels of *SCN5A-6A*.

Because our previous work in *Scn1b* null DS mice showed increased *Scn3a* mRNA, encoding the TTX-S VGSC Na~v~1.3, and increased \[^3^H\]saxitoxin binding, in addition to increased *Scn5a* and Na~v~1.5 protein in the heart ([@bib16], [@bib18]), we asked whether changes in TTX-S VGSC mRNA expression could account for the observed increase in I~Na~. We found no differences in *SCN1A*, *SCN3A*, or *SCN8A* expression in the DS lines compared with controls ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Thus, our results suggest that, while compensatory upregulation of *SCN5A* in response to *SCN1A* haploinsufficiency partially contributed to the observed increases in I~Na~ in the DS lines, changes in TTX-S VGSC expression likely did not play a role.

As expected from previous reports ([@bib8], [@bib10]), the level of *KCNJ2* mRNA (encoding K~ir~2.1) expression was low in all iPSC-CM lines compared with the adult human heart samples (24.4-fold higher in non-failing adult human hearts compared with control iPSC-CM lines; [Figure S3](#mmc1){ref-type="supplementary-material"}A), demonstrating a comparable level of maturity of all iPSC-CM lines tested. *NKX2*.*5*, a marker of cardiac development ([@bib26]), was present in all iPSC-CM lines as well as in human heart samples ([Figures 1](#fig1){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}A).

To determine whether levels of *SCN5A* expression could be used as a potential biomarker for SUDEP, we performed qRT-PCR on autopsy samples obtained from two DS patients who died of SUDEP. When compared with non-failing adult human heart, there were no differences in total *SCN5A*, *SCN5A-6*, or *SCN5A-6A* expression ([Figure S3](#mmc1){ref-type="supplementary-material"}B). We also investigated several common polymorphisms in *SCN5A* that are known to result in gain or loss of function, depending on the presence of other genetic mutations ([@bib1], [@bib4], [@bib11], [@bib14], [@bib21], [@bib28], [@bib36]). We tested the four most likely polymorphisms S524Y, H558R, 1077del, or R1193Q. However, none of the polymorphisms were present in either DS5 or control 2 ([Figure S3](#mmc1){ref-type="supplementary-material"}C).

The large increase in I~Na~ density in DS5 iPSC-CMs compared with controls led to the recommendation that this patient receive a referral to a pediatric cardiologist for evaluation. Annual electrocardiography starting at 4 years of age revealed normal sinus rhythm without evidence of QT prolongation (corrected QT interval = 436 ± 5.4 ms, n = 3) but abnormal T-wave inversions and lateral T-wave flattening ([Figure 3](#fig3){ref-type="fig"}A and [Table S2](#mmc1){ref-type="supplementary-material"}). A 2D echocardiogram showed normal ventricular size and function without significant intracardiac defects (data not shown). Because of the association of autonomic dysfunction in DS patients ([@bib7]), ambulatory 24-hr Holter monitoring was performed. Annual assessment demonstrated normal mean heart rates ([Table S3](#mmc1){ref-type="supplementary-material"}) but very limited heart-rate variability with decreased time-domain parameters (root-mean-square of successive differences = 16.5 ± 1.1 ms and standard deviation of NN intervals = 57.9 ± 4.3 ms, n = 3) and altered frequency domain measurements ([Figure 3](#fig3){ref-type="fig"}B) ([@bib12]).Figure 3Abnormal Electrocardiogram and Limited Heart-Rate Variability in DS Subject 5, Arrhythmogenic Substrates in DS5 iPSC-CMs, and Increased Sodium Current Density in a CRISPR-Generated Heterozygous *SCN1A* Deletion Line(A) Electrocardiogram recordings for DS subject 5 demonstrate normal sinus rhythm, T-wave inversions, and lateral T-wave flattening, abnormal for age.(B) Representative power-spectrum analysis for heart-rate variability from 24-hr ambulatory Holter monitoring demonstrates limited short-term variability as compared with normal values for pediatric patients. Inset: compiled data from annual Holters, n = 3.(C) Representative AP traces showing examples of delayed afterdepolarizations (DADs) in DS5 iPSC-CMs.(D) Quantification of the incidence of early afterdepolarizations (EADs) and DADs in control and DS5 iPSC-CM lines. AP data for Con 2 and DS5 are from two independent differentiations each. ^∗^p \< 0.05.(E) Representative whole-cell I~Na~ traces from *SCN1A* heterozygous deletion (*SCN1A*^+*/*−^) and isogenic control (*SCN1A*^+*/*+^) iPSC-CMs.(F) I~Na~ current-voltage relationships for *SCN1A*^+*/*−^ and *SCN1A*^+*/*+^ isogenic control iPSC-CM cells.(G) Peak I~Na~ is increased in *SCN1A*^+*/*−^ iPSC-CMs compared with the *SCN1A*^+*/*+^ isogenic control line. Peak I~Na~ data for *SCN1A*^+*/*+^ and *SCN1A*^+*/*−^ are from two independent differentiations each. ^∗^p \< 0.05 versus control.Data in (F) and (G) are presented as means ± SEM. See also [Figure S4](#mmc1){ref-type="supplementary-material"}; [Tables S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.

Because patient DS5 exhibited T-wave abnormalities on the electrocardiogram, we recorded APs from control 2 and DS5 lines. We first treated iPSC-CMs with a viral construct to increase the expression of *KCNJ2* to generate a mature resting membrane potential, as described by [@bib32]. We found no differences in the resting membrane potential, threshold, AP duration (at 30%, 50%, 75%, or 90% repolarization), or amplitude between genotypes ([Table S4](#mmc1){ref-type="supplementary-material"}). In contrast, there was an increase in the incidence of delayed afterdepolarizations (DADs) and early afterdepolarizations (EADs) in DS5 compared with the control (86% versus 25% of cells tested, respectively; p = 0.02; [Figures 3](#fig3){ref-type="fig"}C and 3D). DADs and EADs represent potential arrhythmogenic substrates that may exist at the whole-organ level. Their observed increased incidence in DS5 CMs is consistent with the electrocardiogram data as well as our previous observations in DS mouse models ([@bib2], [@bib16]).

We used CRISPR gene editing ([@bib30], [@bib31]) to generate a heterozygous deletion in *SCN1A* (*SCN1A*^+*/*−^) in a control line to ask whether Nav1.1 haploinsufficiency alone was sufficient to increase I~Na~ in iPSC-CMs, or whether this result was dependent on genetic background. The mutant clone used in this study had a heterozygous deletion of a cytosine at position 23 of the *SCN1A* cDNA (c.23del in NM_001165963.2), resulting in a mutation with a proline changed to a histidine at position 8, and a frameshift resulting in a premature stop codon at position 91 (p.P8HfsTer91) ([Figure S4](#mmc1){ref-type="supplementary-material"}). The genotypes of the mutant and control lines were confirmed with next-generation sequencing of PCR amplicons of the targeted locus ([Figure S4](#mmc1){ref-type="supplementary-material"}). The iPSC clones expressed the pluripotency markers SOX2, SSEA4, and OCT4 ([Figure S4](#mmc1){ref-type="supplementary-material"}). Similar to the results in DS patient iPSC-CMs shown in [Figure 2](#fig2){ref-type="fig"}, we found a 1.75-fold increase in whole-cell I~Na~ density in the CRISPR *SCN1A*^+*/*−^ iPSC-CMs compared with *SCN1A*^+*/*+^ isogenic controls ([Figures 3](#fig3){ref-type="fig"}E--3G). In addition, CRISPR *SCN1A*^+*/*−^ iPSC-CMS showed a small but significant negative shift in the voltage dependence of activation as well as a decrease in the slope of the inactivation curve compared with *SCN1A*^+*/*+^ isogenic control ([Table S5](#mmc1){ref-type="supplementary-material"}), consistent with the shift in the voltage dependence of activation observed in DS2 and DS10, as well as the decrease in slope observed in DS4 ([Tables S1](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}).

Discussion {#sec3}
==========

Taken together, our DS patient-derived iPSC-CM and limited clinical data suggest that the high risk of SUDEP in DS results from a predisposition to cardiac arrhythmias in addition to neuronal hyperexcitability, reflecting haploinsufficiency of *SCN1A* in heart and brain and the resulting compensatory overexpression of other VGSC genes in those tissues. We observed increased transient I~Na~ density and rates of spontaneous contraction in DS patient iPSC-CMs. For the subject with the most markedly increased I~Na~ density (patient DS5), increased incidence of arrhythmogenic AP substrates was recorded from iPSC-CMs, and cardiac and autonomic abnormalities were revealed upon clinical evaluation of the patient. This work demonstrates that iPSC-CMs are a valuable model for investigating SUDEP mechanisms in genetic ion-channel epilepsies and uncovering potential biomarkers of SUDEP risk.

Experimental Procedures {#sec4}
=======================

Human Subjects {#sec4.1}
--------------

Fibroblast samples were obtained from human subjects under Institutional Review Board approval as described by [@bib17].

Statistics {#sec4.2}
----------

Results are expressed as mean ± SEM. For contraction rate and electrophysiological recordings, a one-way ANOVA followed by Fisher\'s LSD post hoc test was used to compare iPSC-CM lines. Statistical significance was defined as p \< 0.05.

Detailed methods for the generation of human iPSCs, CRISPR gene deletion, iPSC-CM differentiation and characterization, mRNA expression analyses, *SCN5A* sequencing, immunocytochemistry, MEA recording, and whole-cell voltage-clamp analysis are provided in [Supplemental Information](#app2){ref-type="sec"}.
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